A randomized, controlled trial to increase discussion of breast cancer in primary care

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 7, 2014, Pages 1245-1253

  Kaplan, Celia P ^a,b,c   Livaudais Toman, Jennifer ^a   Tice, Jeffrey A ^a,b   Kerlikowske, Karla ^a,b   Gregorich, Steven E ^a,c   Perez Stable, Eliseo J ^a,b,c   Pasick, Rena J ^a,b   Chen, Alice ^a,b   Quinn, Jessica ^a   Karliner, Leah S ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; BREAST CANCER; CANCER RISK; CLINICAL PRACTICE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENETIC COUNSELING; GENETIC SCREENING; HEALTH STATUS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; PATIENT EDUCATION; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; TELEPHONE INTERVIEW; WAITING ROOM; BREAST TUMOR; DOCTOR PATIENT RELATION; GENETICS; MIDDLE AGED; PRIMARY HEALTH CARE; PROCEDURES; RISK FACTOR;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVIEWS AS TOPIC; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 84904008573     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-1380     Document Type: Article

References (37)

1. NCCN Guidelines-And Derivative Information Products: User Guide. National Comprehensive Cancer Network; 2013.
2. Peplonska B, Lissowska J, Hartman TJ, Szeszenia-Dabrowska N, Blair A, Zatonski W, et al. Adulthood lifetime physical activity and breast cancer. Epidemiology 2008;19: 226-6.
3. Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Energy balance and breast cancer risk: a prospective cohort study. Breast Cancer Res Treat 2006;97: 97-6.
4. Zhang SM, Lee IM, Manson JE, Cook NR, Willett WC, Buring JE. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol 2007;165: 667-76.
5. Physical activity and good nutrition: Essential elements to prevent chronic diseases and obesity at a glance. Atlanta, GA: National Center for Chronic Disease Prevention and Health Promotion, United States Department of Health and Human Services; 2003.
6. Healthy People 2020. Washington, DC: U.S. Department of Health and Human Services; 2010.
7. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002;20: 3328-3.
8. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137: 59-69.
9. Salhab M, Bismohun S, Mokbel K. Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Womens Health 2010;10: 28.
10. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72: 1117-0.
11. Chen S, Parmigiani G. Meta-Analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25: 1329-3.
12. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93: 1633-7.
13. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345: 159-64.
14. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22: 1055-62.
15. Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166: 2260-5.
16. Kaplan CP, Haas JS, Perez-Stable EJ, Des Jarlais G, Gregorich SE. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005;41: 7-5.
17. Kaplan CP, Haas JS, Perez-Stable EJ, Gregorich SE, Somkin C, Des Jarlais G, et al. Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev 2006;15: 162-6.
18. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143: 355-61.
19. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81: 1879-86.
20. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148: 337-7.
21. Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 2009;11: 783-9.
22. Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med 2003;5: 70-6.
23. Levy DE, Garber JE, Shields AE. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med 2009;24: 822-8.
24. Burke W, Acheson L, Botkin J, Bridges K, Davis A, Evans J, et al. Genetics in primary care: a USA faculty development initiative. Community Genet 2002;5: 138-6.
25. Hayflick SJ, Eiff MP. Role of primary care providers in the delivery of genetics services. Community Genet 1998;1: 18-2.
26. Lapham EV, Kozma C, Weiss JO, Benkendorf JL, Wilson MA. The gap between practice and genetics education of health professionals: HuGEM survey results. Genet Med 2000;2: 226-1.
27. Ware JE, Kosinski M, Keller SD. How to score the SF-2 physical and mental health summary scales. 2nd ed. Boston: The Health Institute, New England Medical Center; 1995.
28. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49: 156-63.
29. Bellcross CA. Breast Cancer Genetics Referral Screening Tool (BRST). Peachtree Solutions, LLC; 2013.
30. Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005; 94: 115-2.
31. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295: 2727-1.
32. STATA Statistics/Data Analysis version 11.2. College Station, TX: Statacorp; 2009.
33. Skinner CS, Rawl SM, Moser BK, Buchanan AH, Scott LL, Champion VL, et al. Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. J Gen Intern Med 2005;20: 360-5.
34. Baer HJ, Schneider LI, Colditz GA, Dart H, Andry A, Williams DH, et al. Use of a web-based risk appraisal tool for assessing family history and lifestyle factors in primary care. J Gen Intern Med 2013;28: 817-4.
35. Ruffin MTt, Nease DE Jr., Sen A, Pace WD, Wang C, Acheson LS, et al. Effect of preventive messages tailored to family history on health behaviors: the Family Healthware Impact Trial. Ann Fam Med 2011;9: 3-1.
36. Kaplan CP, Kim SE, WongST, Sawaya GF, Walsh JM, Perez-Stable EJ. Willingness to use tamoxifen to prevent breast cancer among diverse women. Breast Cancer Res Treat 2012;133: 357-66.
37. Medications for risk reduction of primary breast cancer in women. In: Rockville, MD: United States Preventive Services Task Force; 2013.